trastuzumab,trastuzumab deruxtecan,tucatinib
seagen,daiichi sankyo,astrazeneca
 ~ 6m. her2 resistance: development of new ; or loss of her2 expression with all the #her2-directed therapies across tumor types, worthwhile checking. tissue may not always be practical or feasible. #ctdna of value. #wcgic2022 
Oncologist | Researcher | ColorectalCancer #CRCSM???????@MayoClinic @PittTweet Alum; ??#ctDNA #LiquidBiopsies??#PrecisionOncology ViewsMy Own. COI @ASCO #ASCO22